OBJECTIVE： To systematically review the efficacy and safety of the Bushen huoxue lishi category TCM compound in the treatment of chronic prostatitis， and provide evidence-based reference for clinical treatment. METHODS： Retrieved from VIP Database， Wanfang Database， CJFD and CBM， randomized controlled trials （RCT） about Bushen huoxue lishi category TCM compound preparation （test group） versus conventional Western medicine （control group） in the treatment of chronic prostatitis were collected. Meta-analysis was performed by Rev Man 5.3 software after data extraction and quality evaluation. RESULTS： Totally 22 RCTs were enrolled， involving 1 863 patients. Results of Meta-analysis showed the total effective rate [OR＝4.46，95％CI（3.40，5.84），P＜0.001]， total scores of chronic prostatitis symptoms[MD＝－3.62，95％CI（－5.21，－2.04），P＜0.001] and lecithin count[MD＝7.58，95％CI（2.15，13.01），P＝0.006] in test group were significantly higher than control group， prostatic fluid white blood cell count [MD＝－1.68， 95％CI（－3.26，－0.10），P＝0.04] was significantly lower than control group， with significant differences. CONCLUSIONS： Bushen huoxue lishi category TCM compound has good efficacy in the treatment of chronic prostatitis.